RU2018117240A - COMBINED PHARMACEUTICAL COMPOSITION FOR OUTDOOR USE - Google Patents

COMBINED PHARMACEUTICAL COMPOSITION FOR OUTDOOR USE Download PDF

Info

Publication number
RU2018117240A
RU2018117240A RU2018117240A RU2018117240A RU2018117240A RU 2018117240 A RU2018117240 A RU 2018117240A RU 2018117240 A RU2018117240 A RU 2018117240A RU 2018117240 A RU2018117240 A RU 2018117240A RU 2018117240 A RU2018117240 A RU 2018117240A
Authority
RU
Russia
Prior art keywords
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
composition according
mometasone
Prior art date
Application number
RU2018117240A
Other languages
Russian (ru)
Other versions
RU2018117240A3 (en
RU2736940C2 (en
Inventor
Светлана Александровна Копатько
Наталья Владимировна Марченко
Original Assignee
Акционерное Общество "Вертекс"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Акционерное Общество "Вертекс" filed Critical Акционерное Общество "Вертекс"
Priority to RU2018117240A priority Critical patent/RU2736940C2/en
Publication of RU2018117240A3 publication Critical patent/RU2018117240A3/ru
Publication of RU2018117240A publication Critical patent/RU2018117240A/en
Application granted granted Critical
Publication of RU2736940C2 publication Critical patent/RU2736940C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Claims (10)

1. Фармацевтическая композиция противовоспалительного, антибактериального, противогрибкового, регенерирующего действия для наружного применения, содержащая гентамицин, мометазон, эконазол или их фармацевтически приемлемые соли, декспантенол, а также дополнительные вспомогательные вещества, отличающаяся тем, что мометазон или его фармацевтически приемлемая соль в композиции имеет размер частиц 100% менее 20 мкм и 90% менее 10 мкм, эконазол или его фармацевтически приемлемая соль в композиции имеет размер частиц 100% менее 100 мкм и 90% менее 50 мкм.1. A pharmaceutical composition of anti-inflammatory, antibacterial, antifungal, regenerative effect for external use, containing gentamicin, mometasone, econazole or their pharmaceutically acceptable salts, dexpanthenol, as well as additional excipients, characterized in that mometasone or its pharmaceutically acceptable salt in the composition has a size particles 100% less than 20 microns and 90% less than 10 microns, econazole or its pharmaceutically acceptable salt in the composition has a particle size of 100% less than 100 microns and 90% less than 50 microns m 2. Фармацевтическая композиция по п. 1, отличающаяся тем, что содержание гентамицина, декспантенола, мометазона, эконазола или их фармацевтически приемлемых солей в композиции составляет мас. %:2. The pharmaceutical composition according to claim 1, characterized in that the content of gentamicin, dexpanthenol, mometasone, econazole or their pharmaceutically acceptable salts in the composition is wt. %: гентамицин или его фармацевтически приемлемая сольgentamicin or its pharmaceutically acceptable salt 0,01-1,00.01-1.0 декспантенолdexpanthenol 0,5-10,00.5-10.0 мометазон или его фармацевтически приемлемая сольmometasone or a pharmaceutically acceptable salt thereof 0,05-1,50.05-1.5 эконазол или его фармацевтически приемлемая сольeconazole or a pharmaceutically acceptable salt thereof 0,1-5,00.1-5.0
3. Фармацевтическая композиция по п. 1, отличающаяся тем, что в качестве фармацевтически приемлемой соли гентамицина содержит гентамицина сульфат, в качестве фармацевтически приемлемой соли мометазона содержит мометазона фуроат, в качестве фармацевтически приемлемой соли эконазола содержит эконазола нитрат.3. The pharmaceutical composition according to claim 1, characterized in that it contains gentamicin sulfate as a pharmaceutically acceptable salt of gentamicin, contains mometasone furoate as a pharmaceutically acceptable salt, and econazole nitrate as a pharmaceutically acceptable salt. 4. Фармацевтическая композиция по п. 1, отличающаяся тем, что около 10 мас. % мометазона или его фармацевтически приемлемой соли растворено в композиции.4. The pharmaceutical composition according to claim 1, characterized in that about 10 wt. % mometasone or its pharmaceutically acceptable salt is dissolved in the composition. 5. Фармацевтическая композиция по п. 1, отличающаяся тем, что в качестве вспомогательных веществ содержит парафин жидкий или вазелиновое масло или минеральное масло, цетостеариловый спирт, пропиленгликоль, макрогола 6 цетостеариловый эфир, макрогола 25 цетостеариловый эфир, натрия дигидрофосфата дигидрат или одноосновный натрия фосфат, воду очищенную.5. The pharmaceutical composition according to claim 1, characterized in that the excipients comprise liquid paraffin or liquid paraffin or mineral oil, cetostearyl alcohol, propylene glycol, macrogol 6 cetostearyl ether, macrogol 25 cetostearyl ether, sodium dihydrogen phosphate dihydrate or monobasic sodium purified water. 6. Фармацевтическая композиция по п. 1, отличающаяся тем, что содержание вспомогательных веществ в композиции составляет мас. %:6. The pharmaceutical composition according to claim 1, characterized in that the content of excipients in the composition is wt. %: парафин жидкий или вазелиновое масло или минеральное маслоliquid paraffin or liquid paraffin or mineral oil 5-205-20 цетостеариловый спиртcetostearyl alcohol 2-82-8 пропиленгликольpropylene glycol 1-71-7 макрогола 6 цетостеариловый эфирmacrogol 6 cetostearyl ether 0,5-50.5-5 макрогола 25 цетостеариловый эфирmacrogol 25 cetostearyl ether 0,5-70.5-7 натрия дигидрофосфата дигидрат или одноосновный натрия фосфатsodium dihydrogen phosphate dihydrate or monobasic sodium phosphate 0,01-0,10.01-0.1 воду очищеннуюpurified water до 100up to 100
7. Фармацевтическая композиция по п. 1, отличающаяся тем, что выполнена в виде крема, геля, линимента или мази.7. The pharmaceutical composition according to claim 1, characterized in that it is made in the form of a cream, gel, liniment or ointment. 8. Применение фармацевтической композиции по п. 1 для лечения дерматозов воспалительного генеза с сопутствующей бактериальной и микотической инфекцией или высокой вероятностью присоединения вторичной инфекции, простого и аллергического дерматита, атопического дерматита, ограниченного нейродермита, экземы, дерматомикозов, простого хронического лишая.8. The use of the pharmaceutical composition according to claim 1 for the treatment of dermatoses of inflammatory genesis with concomitant bacterial and mycotic infection or a high probability of secondary infection, simple and allergic dermatitis, atopic dermatitis, limited neurodermatitis, eczema, dermatomycosis, simple chronic lichen.
RU2018117240A 2018-04-28 2018-04-28 Combined pharmaceutical composition for external application RU2736940C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2018117240A RU2736940C2 (en) 2018-04-28 2018-04-28 Combined pharmaceutical composition for external application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2018117240A RU2736940C2 (en) 2018-04-28 2018-04-28 Combined pharmaceutical composition for external application

Publications (3)

Publication Number Publication Date
RU2018117240A3 RU2018117240A3 (en) 2019-10-28
RU2018117240A true RU2018117240A (en) 2019-10-28
RU2736940C2 RU2736940C2 (en) 2020-11-23

Family

ID=68500319

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018117240A RU2736940C2 (en) 2018-04-28 2018-04-28 Combined pharmaceutical composition for external application

Country Status (1)

Country Link
RU (1) RU2736940C2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2765470C1 (en) * 2021-03-23 2022-01-31 Иршад Султанович Шарафутдинов Antibacterial agent in form of gel based on gentamycin and 2(5h)-furanone derivative

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2223097C1 (en) * 2002-11-01 2004-02-10 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Combined preparation for treating skin diseases
WO2017091167A1 (en) * 2015-11-28 2017-06-01 Pharmacti̇ve İlaç San. Ve Ti̇c. A.Ş. Topical pharmaceutical composition comprising fusidic acid, isoconazole, dexpanthenol and hydrocortisone

Also Published As

Publication number Publication date
RU2018117240A3 (en) 2019-10-28
RU2736940C2 (en) 2020-11-23

Similar Documents

Publication Publication Date Title
RU2013141845A (en) PHARMACEUTICAL COMPOSITION IN THE FORM OF A CREAM CONTAINING OXYMETAZOLINE FOR THE TREATMENT OF ROSATSEA SYMPTOMS
RU2018119295A (en) PHARMACEUTICAL COMPOSITIONS FOR LOCAL USE FOR TREATMENT OF INFLAMMATORY CONDITIONS
JP6134853B1 (en) Epinastine-containing ophthalmic solution
RU2018117240A (en) COMBINED PHARMACEUTICAL COMPOSITION FOR OUTDOOR USE
RU2006131812A (en) PHARMACEUTICAL COMPOSITION OF ANTI-INFLAMMATORY AND ANTIMICROBIC ACTION IN THE FORM OF OILS ON A HYDROPHOBIC BASIS FOR TREATMENT OF SKIN DISEASES (OPTIONS)
JP2013529201A (en) Tetracycline composition
BR112021026829A2 (en) Compound, pharmaceutical composition, use of a compound, and method for the prophylaxis or treatment of organ fibrosis; liver diseases and disorders; cardiovascular diseases and disorders; cell proliferative diseases and cancers; inflammatory and autoimmune diseases and disorders; diseases and disorders of the gastrointestinal tract; pancreatic diseases and disorders; diseases and disorders associated with abnormal angiogenesis; diseases and disorders associated with the brain; neuropathic pain and peripheral neuropathy; eye diseases and disorders; acute kidney injury and chronic kidney disease; interstitial lung diseases and disorders; or transplant rejection
KR20140000231A (en) Compositions for the treatment of peripheral ulcers of various origins
US10149877B2 (en) Compositions for the treatment of peripheral ulcers of various origins
RU2007128452A (en) PHARMACEUTICAL COMPOSITION OF DOSED AEROSOLS CONTAINING ANTI-ASTHMATIC MEDICINES IN THE FORM OF SUSPENSIONS, SOLUTIONS, EMULSIONS, SOLUTIONS AND EMULSIONS
RU2008147790A (en) PHARMACEUTICAL COMPOSITION BASED ON TILORONES OF LOCAL AND EXTERNAL APPLICATION FOR TREATMENT OF PURULENT DESTRUCTIVE DISEASES OF MUCH AND SKIN, GENERAL DISEASES IN IMMUNO DEFICIENCY CONDITIONS
RU2008147792A (en) PHARMACEUTICAL COMPOSITION BASED ON ACID ACIDONE ACID ACID AND ITS COMPOUNDS FOR TREATMENT OF PURULENT DESTRUCTIVE DISEASES OF Mucous and Skin, General Systemic Diseases in Immune-Deficient
US20210045986A1 (en) Composition for prevention or treatment of skin infection
RU2018141796A (en) STABLE COMPOSITIONS OF LULICONAZOLE FOR LOCAL USE
US20170326193A1 (en) Buchu preparations
US3639623A (en) Topical pharmaceutical composition comprising certain quaternary ammonium compounds
RU2012135798A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT OF SKIN ITCH
RU2017102043A (en) NEW CONNECTION (KS513) ISOLATED FROM PSEUDOLYSIMACHION ROTUNDUM VAR. SUBINTEGRUM, THE COMPOSITION CONTAINING THE SPECIFIED CONNECTION AS A APPLICATION OF THE TOP APPLICATIONS FOR THE PREVENTION OR TREATMENT OF A TREATMENT, FOR THE PREVENTION OR TREATMENT OF THE ALLERGY DISEASES, THE INFLAMMATORY DISEASES, ASTHMA OR THE CHRONIC APPLICATIONS
Veraldi Rapid relief of intertrigo‐associated pruritus due to Candida albicans with isoconazole nitrate and diflucortolone valerate combination therapy
KR101658365B1 (en) Composition for prevention and treatment of skin infection
WO2017057434A1 (en) Aqueous pharmaceutical composition
RU2012134159A (en) MEDICINE FOR TREATMENT OF RAS AND BURNS
BR102022006318A2 (en) MEDICINAL PREPARATION BASED ON ESSENTIAL OILS FOR THE TREATMENT, PREVENTION AND CONTROL OF MASTITIS IN ANIMALS
BG2880U1 (en) Pharmaceutical composition with dermatological effect
RU2007140811A (en) PHARMACEUTICAL PRODUCT FOR OUTDOOR AND LOCAL USE ON THE BASIS OF STEFAGLABRIN